Speaker

Julian trained with Mike Waterfield and Robert Weinberg before setting up his own lab in 1989 at the Cancer Research UK London Research Institute. He moved to the Francis Crick Institute in 2016. His work focuses on the role played by major oncogenes such as RAS and EGFR in human cancer. He established that EGFR is the product of the erbB proto-oncogene and was responsible for mapping out the signaling pathways linking EGFR to RAS and downstream to the MAP kinase and PI 3-kinase pathways. He now focuses on novel approaches to targeting RAS mutant lung cancers, exploring the effects of RAS signaling on suppression of the immune system’s response to the tumour. Julian is a Fellow of the Royal Society, Academy of Medical Sciences, Academy of the AACR, and a Member of EMBO.

« Go Back